Governance Guidance for Biopharma Board Members
Experience-based counsel for the people who sit in the boardroom and make the decisions. Not theory. Not checklists. The real work of governing clinical-stage companies.
Read the LatestWhat We Cover
Governance Fundamentals
The foundational knowledge that generic governance resources don't teach
Browse →Clinical-Stage Decision Making
The board's role in the decisions that define clinical-stage companies
Browse →Capital & Strategic Transactions
Financial governance, fundraising oversight, and exit preparation
Browse →Board Dynamics & Effectiveness
The human and organizational dimensions of board governance
Browse →Recent Articles
When the CEO Wants to Proceed and the Data Says Wait
The most difficult governance moment in a clinical-stage company is not a scandal or a crisis. It is the quiet meeting where a capable, committed CEO wants to advance a program and the data are telling a more cautious story.
Regulatory Strategy Oversight: What the Board Owns and What It Doesn't
Regulatory strategy is where a biopharma company's scientific ambitions meet the agency that decides whether they reach patients. Boards routinely under-govern it — treating it as a technical function rather than the strategic determinant it actually is.
Pipeline Prioritization When Capital Is Scarce
Most clinical-stage companies have more programs than capital. Deciding which to fund, which to slow, and which to kill is among the most consequential — and most avoided — decisions a biopharma board makes.
Stay Informed
A weekly newsletter with governance insights, case studies, and analysis for biopharma board members.
No spam. Unsubscribe anytime.